( NYSE:GSK,NYSE:PFE )

News from ViiV Healthcare A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Aug 16, 2016, 08:55 ET ViiV Healthcare Launches Phase III Programme Evaluating a Two-drug Regimen Combining Dolutegravir and Lamivudine for HIV-1 Treatment

ViiV Healthcare today announced the start of a phase III programme to support regulatory filings for a two-drug regimen of dolutegravir...


Jul 18, 2016, 06:15 ET ARIA Study Shows Superior Efficacy of Triumeq® for Treatment-naïve Women Living with HIV

ViiV Healthcare today presented 48-week data from the phase IIIb, open-label, international, multi-centre ARIA study which showed superior...


Jun 10, 2016, 09:15 ET ViiV Healthcare Announces FDA Approval to Lower the Weight Limit for dolutegravir in Children and Adolescents Living With HIV

Reduction of weight limit to at least 30kg means more children and adolescents will be eligible for dolutegravir   ViiV Healthcare...


Feb 24, 2016, 12:12 ET ViiV Healthcare Announces First Phase II HIV Prevention Study Results for Investigational Long-acting Injectable Cabotegravir

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today presented...


Feb 23, 2016, 14:49 ET ViiV Healthcare Announces Phase II Study Results for First Two Drug, Long-acting Injectable Regimen for HIV-1 Treatment

32 week maintenance data presented at CROI showed comparable viral suppression rates between injectable regimen and three drug oral regimen...


Jan 19, 2016, 08:30 ET ViiV Healthcare & the Los Angeles Department of Health Services Announce New Fellowship Program to Address a Growing Shortage of Primary Care HIV Specialists

 ViiV Healthcare and the Los Angeles Department of Health Services (LA DHS) today announced the launch of the ViiV Healthcare/LA DHS HIV Public...


Jan 07, 2016, 08:31 ET ViiV Healthcare to Progress Collaboration with Janssen to Develop the First Long-acting, Two Drug Injectable Regimen for Treatment of HIV-1 Infection

ViiV Healthcare, a global specialist HIV company with GSK, Pfizer Inc. and Shionogi Limited as shareholders, today formalised its collaboration...


Nov 03, 2015, 08:24 ET ViiV Healthcare Announces Positive Headline Results from a Study of Two Drug Injectable Regimen for HIV Maintenance Therapy

ViiV Healthcare, a global specialist HIV company with GSK, Pfizer Inc. and Shionogi Limited as shareholders, today announced that the Phase IIb...


Oct 26, 2015, 10:27 ET ViiV Healthcare Awards 23 Small Grants to Help Alleviate the Stigma of HIV and AIDS in the MSM and Transgender Community Globally

ViiV Healthcare today awarded its first round of small grants to support men who have sex with men (MSM) and transgender community-led...


Feb 04, 2015, 09:30 ET ViiV Healthcare Announces $10 Million Initiative to Accelerate Response to HIV/AIDS Among Black Gay and Bisexual Men

 ViiV Healthcare today announced the launch of a four-year, $10 million initial investment to fuel a concerted community response to the HIV...


Dec 04, 2014, 11:29 ET Mylan receives tentative FDA approval for paediatric formulations of abacavir/lamivudine through innovative collaboration with ViiV Healthcare and Clinton Health Access Initiative

Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Laboratories Limited has received tentative approval from the U.S. Food and Drug...


Oct 20, 2014, 09:00 ET ViiV Healthcare Expands Program to Reduce HIV Disparities in Southern U.S.

 ViiV Healthcare today announced seven Positive Action Southern Initiative grant awardees in Georgia, Louisiana and Mississippi for...


Aug 25, 2014, 19:32 ET ViiV Healthcare recibe aprobación de la FDA para Triumeq® (abacavir, dolutegravir y lamivudine), una nueva régimen de tableta única para el tratamiento de la infección por VIH-1

El material multimedia relacionado con el aviso a continuación ya está disponible. El material incluye: material complementario en video,...


Aug 25, 2014, 09:00 ET Multimedia assets now available: ViiV Healthcare receives FDA approval for Triumeq® (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection

 On August 22, ViiV Healthcare announced that the US Food and Drug Administration (FDA) approved Triumeq® (abacavir 600mg, dolutegravir...


Aug 22, 2014, 15:46 ET ViiV Healthcare receives FDA approval for Triumeq® (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection

ViiV Healthcare announced today that the US Food and Drug Administration (FDA) has approved Triumeq® (abacavir 600mg, dolutegravir 50mg and...


Jun 10, 2014, 07:00 ET National Survey Identifies Potential Barriers to HIV Treatment Use in U.S.

 ViiV Healthcare today announced new survey data that provide important insights that may help explain why HIV treatment rates remain low in...


Jun 10, 2014, 07:00 ET Una encuesta nacional identifica posibles obstáculos para el tratamiento contra el VIH en los EE. UU.

 ViiV Healthcare anunció hoy nuevos datos de una encuesta que proporciona importantes detalles que pueden ayudar a explicar el motivo por...


Apr 01, 2014, 14:30 ET ViiV Healthcare announces new initiatives to improve access to dolutegravir: licence to the Medicines Patent Pool

ViiV Healthcare today announced new collaborations with the goal of increasing access to its HIV medicine, dolutegravir (marketed under the name...


Mar 19, 2014, 09:45 ET ViiV Healthcare Announces Next Round of the Positive Action Southern Initiative to Support Linkages to HIV/AIDS Care and Treatment Adherence

 ViiV Healthcare today issued a new request for letters of interest (LOIs) for the sixth round of its Positive Action Southern Initiative...


Jan 21, 2014, 06:52 ET ViiV Healthcare's new HIV medicine Tivicay™ (dolutegravir) is approved in Europe

 ViiV Healthcare today announced that the European Commission has approved Tivicay™ (dolutegravir), an integrase inhibitor, for use...


Nov 22, 2013, 09:00 ET Tivicay® (dolutegravir) receives positive CHMP opinion in Europe for the treatment of HIV

 ViiV Healthcare today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has...


Oct 22, 2013, 12:53 ET ViiV Healthcare announces US regulatory submission for a single-tablet regimen combining dolutegravir with abacavir and lamivudine for people living with HIV

ViiV Healthcare today announced the submission of a regulatory application in the United States for its investigational single-tablet regimen (STR)...


Sep 12, 2013, 18:22 ET ViiV Healthcare Presents Positive Data from Phase IIIb/IV Study of Dolutegravir vs Darunavir in Treatment-Naive Adults with HIV-1

 ViiV Healthcare today announced initial results from the Phase IIIb/IV FLAMINGO (ING114915) study. This open-label study, for the first time,...


Sep 04, 2013, 09:00 ET ViiV Healthcare Expands HIV/AIDS Community Support in Hard-Hit Southern U.S.

 ViiV Healthcare announced today the first Positive Action Southern Initiative (PASI) grant awardees in Texas and Virginia and seven grant...


Aug 14, 2013, 19:16 ET ViiV Healthcare anuncia la aprobación de Tivicay® (dolutegravir) en EE. UU. para el tratamiento del VIH-1

ViiV Healthcare tiene el gusto de anunciar hoy que la Administración de Drogas y Alimentos (Food and Drug Administration, FDA) de los...